Eisai agrees licensing deal for Parkinson's drug in Asia

5 April 2017

Japanese drugmakers Eisai (TYO: 4523) and Meiji Seika Pharma have entered into a license agreement for the commercialization of ME2125 (safinamide) for the treatment of Parkinson’s disease in Japan and Asia.

Safinamide, which is marketed in Europe as Xadago, was discovered and developed by Newron Pharmaceuticals (SIX: NWRN). Under a pre-existing licensing agreement, Meiji Seika is entitled to manufacture and commercialize the drug in Japan and Asia.

The company, a subsidiary of Meiji Holdings (TYO:2269), is currently conducting Phase II/III trials for safinamide in combination with levodopa.

Under the terms of the agreement announced today, Eisai will obtain exclusive rights to market safinamide in Japan and to develop and market the drug in Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK